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Background: The aspartic proteinase renin catalyses the first and rate-limiting 
step in the conversion of angiotensinogen to the hormone angiotensin II, and 
therefore plays an important physiological role in the regulation of blood pressure. 
Numerous potent peptidomimetic inhibitors of this important drug target have 
been developed, but none of these compounds have progressed past clinical 
phase II trials. Limited oral bioavailability or excessive production costs have 
prevented these inhibitors from becoming new antihypertensive drugs. We were 
interested in developing new nonpeptidomimetic renin inhibitors. 
Results: High-throughput screening of the Roche compound library identified a 
simple 3,4-disubstituted piperidine lead compound. We determined the crystal 
structures of recombinant human renin complexed with two representatives of 
this new class, Binding of these substituted piperidine derivatives is 
accompanied by major induced-fit adaptations around the enzyme’s active site. 
Conclusions: The efficient optimisation of the piperidine inhibitors was 
facilitated by structural analysis of the renin active site in two renin-inhibitor 
complexes (some of the piperidine derivatives have picomolar affinities for 
renin). These structural changes provide the basis for a novel paradigm for 
inhibition of monomeric aspartic proteinases. 
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Introduction 
The renin-angiotensin system (RAS) is widely accepted 
as a major regulator of cardiovascular and renal function, 
and plays a major role in water and salt homeostasis, as 
well as blood pressure control. Its implication in various 
pathological states has been demonstrated by the efficacy 
of RAS blockers in conditions such as hypertension [l], 
cardiac failure [Z] and left ventricular failure following 
myocardial infarction [3]. In addition, blockers of the RAS 
system are established drugs for renal protection [4,5]. The 
aspartic proteinase renin exclusively cleaves the peptide 
bond between LeulO and Valll in human angiotensino- 
gen to form angiotensin I (Ang I), which is then further 
converted by angiotensin I converting enzyme (ACE) to 
the biologically active vasopressor octapeptide hormone 
Ang II. ACE can be bypassed by the serine proteinase 
chymase [6] and degrades other pharmacologically active 
peptides such as bradykinin. Chymase was recently shown 
to be the major Ang-II-forming enzyme in human heart 
tissue [7]. Ang II is known to act on two receptor sub- 
types, AT, and AT,. With the recently discovered novel 
systems Ang l-7 [S] and Ang 3-8 peptides [9] and their 
specific receptors AT, and AT, with largely unknown 
function, the RAS becomes even more complex. Because 
chymase is not inhibited by .4CE inhibitors and, moreover, 
the available AT receptor antagonists only block recep- 
tors of the AT, subtype, the only totally effective control 
of the RAS system is provided through the inhibition of 
the rate-limiting and highly selective enzyme renin. The 
expected improved efficacy of a renin blocker in the 
tissue systems of the heart and kidneys will potentially 
improve the prevention and treatment of end organ damage 
in these tissues. 
A significant number of peptidomimetic inhibitors of 
human renin designed as stable transition-state analogues 
of the scissile amide bond in human angiotensinogen 
have been developed that reached clinical phase II trials 
[lo-121. Despite the established clinical efficacy of several 
of the inhibitors, almost all development compounds were 
abandoned for reasons of limited oral bioavailability and/or 
excessive production costs [13]. It seemed necessary, there- 
fore, to identify structural classes of nonpeptidomimetic 
renin inhibitors that would satisfy the necessary criteria 
for being more promising drug candidates. High-through- 
put screening of the Roche compound library identified a 
simple 3,4-disubstituted piperidine lead compound (Ia; 
Figure 1). The systematic optimisation of this structural 
class led to piperidine derivatives that have affinities for 
renin in the picomolar range [14]. 
126 Chemistry & Biology 1999, Vol 6 No 3 
Figure 1 
Chemical structures of the 4-halophenyl- 
piperidine compounds la, lb and the 3,4,5- 
trisubstituted piperidine derivative II, which 
inhibit recombinan<human renin with IC,, 
values of 26 uM (la), 5 pM (lb) and 2 nM (II). 
Chemistry B Bdogy 
Understanding the enzyme inhibition at the structural 
level greatly aided the efficient optimisation of this class of 
inhibitors, with respect to specificity and affinity for renin. 
On the basis of the crystal structures of human recombi- 
nant renin complexed with two members of this structural 
class, a 3,4-disubstituted and a 3,4,Strisubstituted piperi- 
dine derivative (Ib and II; Figure l), respectively, a novel 
concept for renin inhibition is presented. The conformation 
of the inhibitors and their interactions with the enzyme will 
be described and an unexpected induced-fit adaptation of 
the enzyme active site will be discussed. 
Results and discussion 
The piperidine compound Ib, trans (3R,4R)-Z-naphthyl- 
methoxy-4-(4-bromophenyl)-piperidine, inhibits human re- 
combinant renin in the low micromolar range (I(& = 5 @VI). 
Structural information about the binding mode of this new 
class of nonpeptidomimetic renin inhibitors was obtained 
by soaking cubic crystals of the glycosylated apoenzyme 
[15] with Ib. Using the protein structure observed in the 
complex with remikiren [ 161 as a model yielded clear mole- 
cular-replacement parameters for the two molecules in the 
asymmetric unit (see the Materials and methods section). 
Despite the moderate resolution of 3.65 A, a subsequent 
F,--F, difference map showed significant extra density in 
the active site of one of the two enzyme molecules present 
in the asymmetric unit. The strongest part of the differ- 
ence density extended from the two essential catalytic 
aspartates, Asp32 and ,4sp215 (pepsin numbering scheme 
is used throughout the text), along the amino-terminal 
side of the substrate cleft. Interpretation of the electron 
density proved difficult, and in our first attempts we 
assumed that the structure of the active site had remained 
the same as observed in the complex with remikiren 
(Figure 2). The best fit to the difference density was 
obtained by having the bromophenyl substituent pointing 
towards the S3 pocket. The inhibitor’s piperidine nitrogen 
could be positioned near the two catalytic carboxylates but 
not close enough to make direct hydrogen bonds. With this 
very tentative interpretation, extensive structural varia- 
tions in the 3-, 4- and 5substituent positions appeared 
possible and, indeed, some highly potent compounds such 
as the 3,4,5trisubstituted piperidine derivative II were 
obtained. The emerging structure-activity relationship soon 
became inconsistent with this binding hypothesis, however. 
Revision of the binding hypothesis, based on induced- 
fit adaptations around the enzyme’s active site, became 
obvious once the complex with the 3,4,5trisubstituted 
piperidine derivative (II; IC,, = 2 nhl) was crystallised in a 
tetragonal, better-diffracting crystal form. 
Figure 2 
Molecular surface of the Sl_ and S3-binding pockets [341 in a 
complex of human recombinant renin with the peptidomimetic inhibitor 
remikiren. The sidechain of Trp39 is shown in light blue. The two 
catalytic residues, Asp32 and Asp21 5, are indicated. The trace of the 
flap region ranging from residue Thr72-Ser81 is indicated in yellow, 
as is the sidechain of Tyr75. The SB-binding pocket is located on the 
rear side of the protein. This and the following surfaces were 
generated and displayed using the program GRASP 1351. For clarity 
only the fragments lle20, Lys26-Glu31, Thr33-Ser36, Val40-Ser42, 
Cys45-Phe46 and Glul03-Glyl22 have been taken into account, 
and single-letter amino-acid code is used. 




2-chloro-benzoate II binding to human 
recombinant renin. The inhibitor in the active 
site is shown in ball-and-stick representation 
in white. (a) In the overall view, 5 strands are 
represented as arrows and 0: helices as 
ribbons. The flap region ranging from residue 
Thr72-Ser61 is light blue. Catalytic residues 
Asp32 and Asp21 5 and the sidechains of 
Trp39 and Tyr75 are shown. (b) The close-up 
view indicates the structural differences 
between the active site as observed in a 
complex with the peptidomimetic inhibitor 
remikiren [16] (yellow) and the piperidine 
derivative II (light blue). Hydrogen bonds are 
represented by dotted lines. The figure was 
produced using the programs MOLSCRIPT 
[361 and RASTERBD 1371. 
( a) W 
T72 
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Structure determinafion of the complex of renin with 
compound II at 2.9 A resolution permitted an unambigu- 
ous interpretation of the binding mode of this potent 
inhibitor and revealed some dramatic structural changes in 
the protein structure. In the refined structure, the proto- 
nated nitrogen of the piperidine moiety is positioned 
between the two catalytic aspartates, Asp32 and Asp215, 
such that it forms two strong hydrogen bonds with the 
enzyme. The lipophilic 2-naphthyl-methoxy substituent at 
position 3 occupies the large hydrophobic and contiguous 
subsites Sl and S3, which accommodate the Pl cyclohexyl 
and P3 phenyl sidechains of the peptidomimetic inhibitors 
CGP 38’560 [17] and remikiren [16], respectively. This 
nonpeptidomimetic inhibitor, therefore, lacks the P2 and 
the P4 portions, as well as the backbone of classical transi- 
tion-state mimics. Given the orientation of the piperidine 
ring between the two catalytic aspartate residues, the large 
substituent at position 4 can only be accommodated by 
inducing major conformational changes in the protein 
structure compared with what is seen in the apoenzyme 
structure and in all the known structures of enzyme-transi- 
tion-state analogue complexes [16-201. The phenyl moiety 
at position 4 points towards the former carboxy-terminal 
boundary of the Sl pocket (Figures 2 and 3) occupied by 
the flap (Thr72-Ser81) or, more specifically, by the side- 
chain of Tyr7.5 in the closed structures. To make room 
for this part of the inhibitor, the flap shifts into a more 
open conformation and the sidechain of Tyr7.5 swings 
outwards through an approximately -120” 21 rotation. This 
opening and rearrangement of the flap is not sufficient to 
provide space for the o-chlorobenzoyloxymethyl moiety of 
the 4-substituent (4’ substituent), however. This is achieved 
by additional displacement of the Trp39 sidechain, which 
flips into a new position. Closer examination of the struc- 
ture of the residues shaping the cavity burying either the 
Trp39 sidechain or the 4’ substituent reveals some inter- 
esting aspects. In the complex with remikiren. the indole 
nitrogen of Trp39 makes a hydrogen bond with the pheno- 
lit OH functional group of Tyr75, but the indole side- 
chain is otherwise buried in a hydrophobic environment 
provided by the conserved residues Val40, Prdl, Va180, 
Val104, Met107, Phel12, Aspll8, Gly119 and Val120. In 
the complex with compound II, the cavity formerly occu- 
pied by the indole ring of Trp39 is entirely filled with the 
o-chlorophenyl moiety of the inhibitor. The somewhat dif- 
ferent shape of the inhibitor moiety is very well accommo- 
dated through a number of small changes in mainchain 
and sidechain conformations of the cavity-forming residues. 
The only unfavourable consequence of the burying of 
the 4’-substituent is that the carbonyl oxygen of the ester 
moiety has no hydrogen-bonding partner. In its new posi- 
tion, essentially reached by a -120” ~1 and a 180’ ~2 rota- 
tion, the Trp39 sidechain is again almost completely buried 
in a hydrophobic environment, its benzene ring being 
covered by lipophilic sidechains of the flap region (mainly 
the sidechains of Leu71, Leu73 and Va180). The only 
solvent-accessible part of Trp39 is the indole nitrogen. 
The equatorial methoxymethyl function at position 5 points 
towards the flap region and just about touches one edge of 
the Tyr7.5 sidechain but does not contribute significantly to 
the high affinity of this inhibitor. 
It was reasonable to believe that the related but lower- 
affinity compound Ib would bind to renin using a similar 
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Figure 4 
Comparison of the molecular surfaces of the 
binding pockets in a complex of human 
recombinant renin with the piperidine 
compounds (a) lb and (b) II. The sidechain of 
Trp39 is light blue. The two catalytic residues 
Asp32 and Asp21 5 are indicated. The 
orientation is approximately orthogonal to that 
of Figure 3. For clarity, the flap region is not 
shown. 
binding mode to compound II. Indeed, re-examination 
of the difference density obtained from the renin-Ib 
complex shows it to be very compatible with such a 
binding mode; the flap of the enzyme opens, which leads 
to the loss of the intramolecular hydrogen bond between 
the phenolic OH functional group of Tyr75 and the ring 
nitrogen of Trp39. There is no evidence, however, that 
the sidechain of Trp39 flips out of its pocket (Figure 4a), a 
structural alteration that is observed for the extended 
substituent at the 4’ position of compound II (Figure 4b). 
The introduction of the o-chlorobenzoyloxymethyl sub- 
stituent (at the 4’ position of compound II) leads to an 
increase in renin binding affinity by more than 250-fold. 
The interface area between the essentially solvent-inac- 
cessible 4’-substituent and the enzyme is about 130 AZ, 
which translates into about 4 kcal/mol binding energy, 
using typical values for hydrophobic interactions [Zl]. 
The fact that this is not far from the gain in affinity sug- 
gests that the induced conformational change, the further 
opening of the flap and the relocation of Trp39, is not 
too costly in terms of energy. The observed IC,, of 2 r&l 
for compound II is in the range obtained with highly 
potent peptidomimetic inhibitors such as remikiren [16] 
and CGP 38’560 [ 171. 
Dramatic alteration of the shape of a binding site upon 
ligand binding is well documented for antibodies [22--251. 
In the case of progesterone binding to its monoclonal 
anti-progesterone antibody DB3, the indole sidechain of 
TrpHlOO adopts two different conformations, intercon- 
verting between ‘open’ and ‘closed’ forms of the anti- 
body-combining site. The indole appears to be acting as 
an antibody-derived surrogate for its own hydrophobic 
pocket [26]. The observed induced-fit adaptations of the 
renin active site suggest that aspartic proteinase active 
sites have latent conformational flexibility. The main- 
chain and sidechain alterations of the binding pockets 
obviously depend on the substitution pattern of the 
piperidine moiety and provide sufficient variability for 
improved selectivity. Recently. the first crystal structure 
of plasmepsin II, a protein from Plasmodium falciparum, 
was reported [27]. The enzyme belongs to a group of two 
homologous monomeric aspartic proteinases, plasmepsin 
I and II, that are essential components of the hemoglo- 
bin-degradation pathway of P. fahparum. Indeed, com- 
pound II inhibits plasmepsin I and II with IC,, values 
of about 1 @I (data not shown). These observations 
suggest that the induced-fit adaptations observed for renin 
are of a more general nature and might therefore repre- 
sent a novel paradigm for the inhibition of monomeric 
aspartic proteinases. 
Significance 
Renin, an aspartic proteinase, plays an important phys- 
iological role in the regulation of blood pressure. It 
catalyses the first and rate-limiting step in the conver- 
sion of angiotensinogen to the hormone angiotensin II. 
Although many potent peptidomimetic inhibitors of renin 
have been synthesised, none have been developed into 
antihypertensive drugs. A novel class of nonpeptido- 
mimetic inhibitors have been developed here. Struc- 
tural analysis reveals that binding of these piperidine- 
derived compounds to renin requires major conforma- 
tional changes in the enzyme active site. Major changes 
to the shape of binding sites upon ligand binding have 
been well documented in antibodies 122-251. The observed 
induced-fit adaptations of the renin active site suggest 
that aspartic proteinase active sites have latent confor- 
mational flexibility. This would be in agreement with 
the observation that piperidine derivatives also inhibit 
plasmepsin I and II from Hasmodium falciparum. The 
induced-fit adaptations observed for renin therefore could 
be of a more general nature, and might represent a novel 
paradigm for the inhibition of monomeric aspartic pro- 
teinases. The fact that the piperidine moiety can be an 
efficient binding partner for the catalytic aspartic acid 
residues suggests it could be used as a central template for 
aspartic proteinase inhibitors. 
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Materials and methods 
Recombinant human renin, produced in Chinese hamster ovary (CHO) 
ceils [161, was crystallised in the apo form (form I) as described by Lim et 
a/. [151 and in the inhibited form (form II) as described by Rahuel et al. 
[17]. Form I crystals belong to the cubic space group P2,3 with cell 
dimensions a= b = c = 143.3 A, and crystal form II has space group 
P4,2,2 with a = b = 93.1 A, c = 111.2 A. For soaking experiments, native 
crystals were placed in 400 pl stabilising solution, containing a molar 
excess of the inhibitor lb. A complex of renin with compound II was pre- 
pared by adsorbing purified apo-renin onto an affinity column to which 
a weak peptidomimetic renin inhibitor had been covalently coupled. 
Bound renin was then eluted with a solution of compound II. Excess 
inhibitor was removed by diafiltration. This approach was necessary due 
to its limited solubility in aqueous buffers. Diffraction data for both 
crystal forms were recorded at room temperature on a SiemenslNicolet 
area detector installed on an Elliot GX-21 rotating anode generator 
operated at 40 kV, 80 mA and equipped with a graphite monochroma- 
tor. Data processing was performed with the XDS software [28] and 
data reduction with the CCP4 suite [29]. The data collection statistics 
for crystal forms I and II were as follows: number of measurements, 
37608157052; number of independent reflections, 11033/l 0998; com- 
pleteness (O/o), 98.3 (to 3.65 A)/97.1 (to 2.9 A); R,,,,=0.045/0.069 
RWge =x11(k)-(1)1/11(k), where I(k) and (I) are the intensity values for 
individual measurements and of the corresponding mean values; the 
summation is over all measurements). The structure of the binary complex 
with the trans (3R,4R)-2-naphthylmethoxy-4-(4-bromophenyl)-piperidine 
[lb] was solved by molecular replacement using MERLOT software [301 
using the refined coordinates of the recombinant human enzyme as 
determined in the binary complex with remikiren [16]. The results 
obtained for the rotation and translation searches correspond to those 
published by Dhanaraj et al. [201. Rigid body refinement converged to an 
R-factor of 21.4%. An F,-F, difference electron density map (where F, 
and F, are the observed and calculated structure factors, respectively) 
was calculated using the phases of the refined coordinates. Rigid body 
refinement of the binary complex with remikiren followed by positional 
and restrained B-value refinement performed with X-PLOR 1311 con- 
verged to a final R-factor (R=Z~jFOl-IF,Il/~lF,,) of 16.0% for 10980 
reflections at 2.9 8, for the data of the binary complex with compound II. 
Parameters for ideal stereochemistry were used as described by Engh 
and Huber (321, manual rebuilding was performed using the in-house 
graphics program MOLOC 1331. The root-mean-square deviation from 
target values for bonds and angles is 0.018 A and 2.22’, respectively. 
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